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Abstract
In 2011, a novel strain of O104:H4 Escherichia coli caused a serious outbreak of foodborne hemolytic uremic syndrome and
bloody diarrhea in Germany. Antibiotics were of questionable use and 54 deaths occurred. Candidate therapeutic
bacteriophages that efficiently lyse the E. coli O104:H4 outbreak strain could be selected rather easily from a phage bank or
isolated from the environment. It is argued that phage therapy should be more considered as a potential armament against
the growing threat of (resistant) bacterial infections.
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Introduction
From May to July 2011, Germany was struck by the largest
outbreak of hemolytic uremic syndrome (HUS) and bloody
diarrhea caused by Escherichia coli ever reported [1]. A total of
3,816 cases were reported, 845 (22%) of which involved HUS.
This high rate of HUS was the first indicator that the bacterial
cause of illness was not a typical enterohaemorrhagic E. coli
(EHEC) strain [2]. It was shown to be a highly pathogenic
enteroaggregative E. coli (EAEC) strain, which in addition carried
the EHEC genes for the classical HUS-associated Shiga toxin 2
[3–4]. Notwithstanding the timeliness of the German surveillance
system (reporting occurred faster than required by law) for HUS
and Shiga toxin-producing E. coli notifiable diseases [5], no less
than 54 patients died. Eventually, sprouts were identified as the
most likely outbreak vehicle [6]. The outbreak strain was resistant
to beta-lactam antibiotics and third-generation cephalosporins and
was partially resistant to fluoroquinolones, but sensitive to
carbapenems and ciprofloxacin [1]. However, a Cochrane
database review analyzing seven randomized controlled clinical
trials of pediatric HUS associated with EHEC infections found no
benefit of antibiotic treatment over supportive therapy alone [7].
Moreover, the use of antibiotics to treat Shiga toxin producing E.
coli infections has been discouraged because it has been shown to
release toxins. The genes for the Shiga toxin are actually not
bacterial genes, but (bacterio)phage genes. When an E. coli
bacterium gets infected with a temperate phage harboring a Shiga
toxin gene, upon integration of the phage genome (as prophage)
into the bacterial genome (lysogeny), it can be expressed by the
bacterium, which then becomes pathogenic. Some types of
antibiotics have been shown to induce the so-called SOS response
in bacteria, i.e. a ubiquitous response to DNA damage, which
induces phage replication and lytic cycle [8]. As such, the use of
antibiotics may be helping Shiga toxin genes to spread. Phage-
mediated transfer of bacterial virulence, fitness and antibiotic
resistance is a negative (from the human point of view)
consequence of bacterial phage coevolution.
Paradoxically, phages from a very different, constitutionally lytic
genus could also help fight EHEC and EAEC. Phages do play a
major role in controlling bacterial densities in the biosphere,
including humans, which is the basis of sustainable phage therapy
[9]. For example, phages appear to be key players in ending
cholera epidemics. Faruque et al. [10] observed that seasonal
epidemics of cholera inversely correlated with the prevalence of
environmental cholera phages. Phages could be used therapeuti-
cally, as an additional tool or in combination with antibiotics, to
treat bacterial infections that do not respond to conventional
antibiotics. Importantly, they can be chosen to be harmless to the
commensal bacteria, such as those of the gut microflora. The oral
application of phages to humans is likely to be very safe [11] and
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several phage based preparations were given regulatory approval
and are commercially available for the decontamination of foods
[12]. Muniesa et al. [13], in a review on experimental treatment
and prevention options for HUS, reported phages to be an
effective tool for disinfection of various vegetables and meat
products contaminated by E. coli strain O157. Steers that received
phage by the rectal route showed a 100-fold fecal titer decrease of
O157 compared to controls. In sheep, oral T4-like coliphage
reduced the O157 counts in the caecum and rectum. Recently,
French scientists isolated three morphologically different types of
tailed phages that infect E. coli O104:H4. The cocktail of all three
phages showed sustained replication in the intestines of mice, but
without decreasing the intestinal titer of O104:H4 cells [14].
Here we present the results of an ad hoc multidisciplinary
working group, including institutions involved in infectious
diseases surveillance, phage therapy and molecular biology
research, which set out to isolate, select and characterize candidate
therapeutic phages active against the E. coli O104:H4 outbreak
strain.
Materials and Methods
Isolation and selection of E. coli O104:H4 phages were
performed according to the methods described by Merabishvili
et al. [15]. Considering laboratory safety in the handling of EHEC,
all manipulations involving the O104:H4 outbreak strain were
performed in a dedicated biosafetylevel 3 facility. A set of 16
phages known to infect E. coli was screened against the outbreak
strain. The set included the well-known T4 phage, nine phages
from the therapeutic phage library of the Eliava Institute of
Bacteriophage, Microbiology and Virology in Tbilisi (Georgia)
and six phages that were recently isolated from wastewater of the
Queen Astrid Military Hospital in Brussels.
The lytic potential of the 16 phages was tested on a collection of
92 E. coli strains using the horizontal bacterial strips method on
agar plates [15]. The tested collection included ten different
pathogenic E. coli serotypes (Table 1) and 82 clinical and non-
clinical E. coli strains.
Phage genome sequence was determined by pyrosequencing
(454 technology) according to Kropinski et al. [16] and analyzed
according to Vandersteegen et al. [17]. Open reading frames were
predicted, and their functions defined, by ORF finder (http://
www.ncbi.nlm.nih.gov/projects/gorf/), GeneMarkTM [18] and
BLASTp [19] programs, followed by manual confirmation.
EMBOSS stretcher [20,21] was used to compare DNA homology
between phages.
Results and Discussion
Only one out of 16 phages, myovirus GEC-3S (Fig. 1) from the
Eliava collection, showed activity against the outbreak strain. In
addition, two myoviruses, QAMH-FFP.1 and QAMH-NES.1,
were newly isolated from the wastewater of the Brussels Military
Hospital using the culture enrichment method with the original
outbreak strain as the host. In contrast to phages QAMH-FFP.1
and QAMH-NES.1, phage GEC-3S could be propagated in E. coli
strain K12 and this without significant decrease of titer or activity
against strain O104:H4, which is not negligible in the context of
an eventual production of therapeutic or prophylactic phage
preparations. The non-pathogenic K12 strain is commonly used in
Good Manufacturing Practices (GMP) and clean-room compliant
preparation of medicinal products, whereas the handling of the
O104:H4 strain requires strict biocontainment precautions.
Phages QAMH-FFP.1 and QAMH-NES.1 showed no activity
against the K12 strain. Of the ten tested pathogenic E. coli
serotypes, only two – O104:H4 and O125:K70– were susceptible
to phage GEC-3S (Table 1). The overall activity of the phage
against 92 pathogenic and non-pathogenic E. coli strains proved to
be 20.7% (19/92). Complete genome sequencing (Accession
number HE978309) revealed that phage GEC-3S belongs to the
genus of T4-like viruses with high similarity to the representatives
of the RB49 group. Two hundred and seventy-six open reading
frames were predicted and their functions were defined. At the
Table 1. Susceptibility of ten pathogenic E. coli serotypes to infection with phage GEC-3S.
Serotype
O26:K60 O55:K59 O86:K61 O104:H4 O111:K58 O111:K60 O125:K70 O128:K67 O142:K86 O157:H7
GEC-
3S
2 2 2 cl 2 2 cl 2 – –
2, no lysis; cl, confluent lysis.
doi:10.1371/journal.pone.0052709.t001
Figure 1. Transmission electron micrographs of myovirus GEC-
3S. Phage particles were analyzed by transmission electron microscopy
as described by Imberechts et al. [27]. The head is somewhat elongated,
appears hexagonal in outline and has a mean diameter of 102 nm
(SEM=3 nm). The head is separated from the tail by a neck. The tail is a
rigid, contractile tube with a mean length of 109 nm (SEM=1 nm). It
appears cross-banded, suggesting helical symmetry. The tail ends in
short and long fibers. The latter do not show up very well on this
micrograph.
doi:10.1371/journal.pone.0052709.g001
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nucleotide level, GEC-3S showed high homology to phi1, RB49
and JSE phages, respectively 94.6, 93.6 and 88.0%. The shared
differences between GEC-3S and the other phages are spread
throughout the whole genome and in particular in the regions
between 39,000–40,000, 67,000–68,000, 100,000–110,000 and
115,000–125,000 bp, loci which mostly comprise ORFs coding for
small hypothetical proteins and homing endonucleases (Fig. 2).
Phage GEC-3S harbors six unique genes that are not present in
the genomes of the other representatives of the RB49 group
(phi1p263, RB49p263, EpJSE_00266) (Table 2). Four of these
genes are ORFans, while the other two are coding homing
endonucleases, extremely widespread enzymes in T-even-like
phages according to available genomic data [22]. The only gene
that is typical for the other three phages from this group, but is not
Figure 2. Pairwise DNA homology of GEC-3S and phi1, GEC-3S and RB49, GEC-3S and JSE, compared using a sliding window of
50 bp.
doi:10.1371/journal.pone.0052709.g002
Table 2. ORFs of phage GEC-3S not presented in any other representative of the RB49 group.
N Amino acid length E value Putative functions/Known Homologs*
ORF 63 251 5610216 putative homing endonuclease RB16 6 (Enterobacteria phage RB16)
ORF 137 246 161029 putative H-N-H-endonuclease P-TflX (Enterobacteria phage T5)
ORF 163 32 – ORFan
ORF 171 44 – ORFan
ORF 265 80 – ORFan
ORF 266 66 – ORFan
*Putative functions and known homologs of ORFs were identified using BlastP against the non-redundant database.
doi:10.1371/journal.pone.0052709.t002
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present in GEC-3S is a hypothetical protein of 51 amino acids
length (Table S1).
Being a T4-like phage (of the RB49 group), much is known
about the properties and safety of phage GEC-3S, further
strengthening its appropriateness for therapeutic applications. In
general, temperate phages are considered inappropriate for use as
therapeutic phages because they can transduce unwanted genes.
Sequence similarity searches against the non redundant NCBI
database confirmed the lytic (non temperate) character of phage
GEC-3S and the absence of genes known to encode virulence or
pathogenicity associated, or potentially allergenic, proteins. This is
important, as the E. coli outbreak strain itself is a good illustration
of phage-mediated increased pathogenicity.
Because sequencing of the O104:H4 outbreak strain failed to
provide clues about its origin and evolution, it is unclear
whether we may expect similar upcoming outbreaks to occur
recurrently or spontaneously in the future [23]. Even though the
epidemic has been declared finished, the health community
should explore new (prophylactic) therapies. Theoretically,
phage GEC-3S could have been used to help control (in
humans, animals, the environment or food) the O104:H4
outbreak that caused the death of more than 50 patients. A
cocktail of purified and fully defined and safe phages selected
against the most problematic EHEC and EAEC strains could be
produced and stored as an additional antimicrobial when an
outbreak similar to the one witnessed in Germany occurs in the
future. The high bacterial strain specificity of phages make it
necessary to provide cocktails for treatment of disease. If
required, new phages could be added to the cocktail. The
isolation and selection process of the here presented phages took
only 3 days to complete. A useful strategy would be to set up an
international bank by isolating a large number of phages from
E. coli-pathogen-rich sites using strain K12, checking their
ability to grow efficiently on all the important pathogenic E. coli
strains available (e.g. O104:H4), and from these choosing a set
that provides broad coverage of the known problem strains. It
would be an advantage if these were T4-related phages, about
which so much is known. Ideally, component phage identifica-
tion and detailed characterization and maintenance of this bank
should be supported by WHO and/or the European and
American CDCs [24]. The O104:H4 outbreak caused consid-
erable suffering and resulted in a strain on healthcare and public
health systems [25], which could provide an incentive for
competent authorities and physicians to use phages, as
additional tools, in the prevention and treatment of otherwise
virtually untreatable infections. Meanwhile, preventive micro-
biology remains crucial for early detection of major health
threats caused by infectious diseases [26].
Supporting Information
Table S1 Comparison of ORFs/genes of phage GEC-3S
with other representatives of the RB49 group.
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